Cereset

The question every prospective franchisee must answer before committing six figures to a wellness concept is whether the underlying technology is a genuine clinical breakthrough or an expensive novelty. For Cereset, the evidence points toward the former. Founded in 2004 by Lee Gerdes, a physicist, mathematician, computer software expert, and psychology student, Cereset emerged from a deeply personal origin story: following a violent attack in 1992 that left Gerdes suffering nearly a decade of sleeplessness, he channeled his multi-disciplinary expertise into developing a non-invasive technology to help the brain restore its own natural equilibrium. The company evolved from Brain State Technologies, which Gerdes conceptually initiated in 2000 and formally incorporated in 2004, and in 2018 the organization transitioned from a licensing model to a consumer franchise brand, adopting the name Cereset, a portmanteau of "cerebrum" and "reset." Headquartered in Scottsdale, Arizona, Cereset began offering franchises that same year, positioning itself within the offices of mental health practitioners category at a moment of extraordinary industry expansion. The patented BrainEcho technology, the commercial engine of the entire franchise system, uses sensors to detect real-time brain rhythms and echoes them back to the client as audio tones, guiding the brain into a relaxed, harmonious state without drugs, devices that alter neural activity externally, or any invasive procedure. The legacy technology upon which BrainEcho was built has now served over 130,000 clients across 25 countries, providing a substantial clinical track record that distinguishes this Cereset franchise opportunity from early-stage wellness concepts launching without peer-reviewed research. As of 2025, Cereset has grown to approximately 59 to 60 total franchise locations, with a confirmed 58 franchised units and at least three international locations in Europe alongside its U.S. footprint. Entrepreneur magazine recognized Cereset as a Top New Franchise, a validation that adds third-party credibility to the brand's positioning as a category-defining concept in neuro-wellness.

The industry context surrounding a Cereset franchise investment is one of the most compelling structural backdrops in franchising today. The global mental health market was valued at USD 95.03 billion in 2025 and is projected to grow from USD 98.19 billion in 2026 to USD 115.63 billion by 2031, representing a compound annual growth rate of 3.32% over that forecast period. Within that broader market, the U.S. outpatient psychiatry segment alone was estimated at USD 15.88 billion in 2024 and is forecast to reach USD 39.22 billion by 2033, compounding at a remarkable 10.63% annually. That outpatient growth rate is nearly three times faster than the overall mental health market, and it reflects the accelerating preference among American consumers for accessible, non-hospital mental wellness services delivered in community-based settings, precisely the model a Cereset franchise occupies. Approximately 60.1 million adults in the United States received some form of mental health treatment in 2024, and depression alone commanded a 35.18% revenue share of the global mental health market that year, with anxiety disorders holding approximately 25% market share. Post-traumatic stress disorder is projected to expand at a 5.22% CAGR through 2031, a segment directly relevant to Cereset given that its Cereset Research division is currently conducting IRB-approved clinical trials for PTSD at institutions including Womack Army Medical Center, Wake Forest School of Medicine, and Uniformed Services University. North America generated 38.25% of total global mental health revenue in 2025, supported by high per-capita health spending and 14 U.S. states now enforcing mental health parity legislation that equates behavioral and physical health coverage. The convergence of aging demographics, workplace stress normalization, post-pandemic mental health awareness, and the growing legitimacy of non-pharmaceutical interventions creates a secular tailwind that is structurally advantageous for a Cereset franchise in nearly any geography.

Understanding the full cost of a Cereset franchise investment requires disaggregating the capital requirements across several distinct categories. The initial franchise fee is $35,000, paid upfront upon signing the Franchise Agreement, which is consistent with mid-tier health and wellness franchise concepts and positions Cereset as an accessible entry point compared to medical spa or physical therapy franchise models that routinely demand franchise fees of $50,000 or more. The total estimated initial investment ranges from approximately $102,900 to $226,600 depending on geography, lease terms, and build-out requirements, with an alternative disclosure range of $91,300 to $205,000 appearing in some FDD versions. The widest line-item variance in the investment range comes from working capital, estimated at $9,000 to $50,000 for three months of operations, and the startup package, which includes proprietary WaveView hardware interface, sensors, and a desktop computer and ranges from $34,500 to $63,500. Additional cost categories include initial training fees of $2,500 to $10,000, a lease deposit and three months of rent estimated at $4,000 to $12,000, build-out and improvements of $1,000 to $10,000, signage at $3,000 to $10,000, and professional fees of $1,500 to $6,500. Insurance premiums for the first 12 months are estimated at $2,500 to $3,500, and grand opening advertising carries a budget of $2,000 to $5,000. The minimum liquid capital requirement is cited at $25,000, though the working capital range suggests franchisees should approach this investment with considerably more available cash, particularly in markets where lease costs push toward the higher end of the range. Ongoing fees include a royalty rate of 8% to 10% of gross sales and an advertising or national brand fund contribution of 2% to 4% of gross sales, bringing total ongoing fee obligations to a range of 10% to 14% of gross revenue. Prospective investors should note that the royalty and advertising fee combination on the higher end of those ranges is above the franchise industry average, which typically runs 5% to 7% royalty and 1% to 2% advertising, making revenue generation efficiency especially important for franchisee profitability.

The daily operating model of a Cereset franchise centers on delivering individualized brain-balancing sessions using the proprietary BrainEcho technology in a calm, consultative environment. Franchisees are not required to have prior experience in technology or medical fields, which broadens the candidate pool significantly, but consistent protocol adherence is essential given the specialized nature of the equipment and client-facing neuro-acoustic sessions. The initial training program is four weeks in duration and conducted at Cereset's operational training headquarters in Grand Rapids, Michigan, delivering over 75 hours of classroom instruction plus additional hours of hands-on, on-the-job training covering BrainEcho equipment operation, brain rhythm data interpretation, client session facilitation, and day-to-day business management. Ongoing support structures include brand awareness programs, marketing content production by the corporate team, research updates, construction assistance for new locations, and field-level consultation after opening. Cereset produces social media content on behalf of franchisees, freeing owner-operators to focus their time on direct client engagement rather than digital marketing execution. The corporate team also supports franchisees with research infrastructure, including access to Cereset Research findings, which now encompass 15 peer-reviewed publications, 80 abstracts and presentations, and over 10 IRB-approved clinical trials with more than 1,000 clinical trial participants, providing franchisees with credible scientific collateral for local marketing. Territory protection is built into the franchise agreement, with exclusive geographic areas defined by population parameters to prevent market saturation within the system and ensure each franchisee has a viable client acquisition base. Cereset encourages franchisees to pursue grassroots community engagement strategies, including health fairs, church presentations, and neighborhood meetings, supplementing the corporate-produced digital content with high-trust, local relationship-building.

Item 19 financial performance data is not disclosed in the current Franchise Disclosure Document, meaning Cereset has elected not to provide average revenue, median revenue, or profit margin figures to prospective franchisees through the FDD. This is a meaningful data gap for investors conducting due diligence and represents a common practice among younger or growth-stage franchise systems that have not yet accumulated a statistically significant or uniformly performing cohort of units from which to draw defensible averages. The absence of Item 19 disclosure shifts the burden of financial validation entirely onto the prospective franchisee, who must independently conduct validation calls with existing franchise owners and model their own unit economics based on local market research. What can be assessed from publicly available information is the growth trajectory of the system: Cereset launched franchising in 2018, reported 16 operating locations by March 2019, and has grown to approximately 58 to 60 franchised units by 2025, representing a net addition of more than 40 units over roughly six years, or an average of approximately seven new units per year. Industry benchmarks for boutique wellness and neuro-technology practices suggest that a well-positioned location in a mid-to-upper-income market can generate meaningful revenue given the premium pricing that clients typically accept for non-pharmaceutical brain wellness services. The total investment ceiling of approximately $226,600 means that even at relatively modest revenue levels, a franchisee with controlled operating costs and strong client retention could achieve a payback period that compares favorably to higher-capital wellness concepts. The Cereset franchise cost structure, anchored by the proprietary technology package rather than large physical infrastructure, creates a relatively asset-light model that limits ongoing capital expenditure obligations beyond routine equipment maintenance and software updates. Prospective investors should request current validation directly from operating franchisees, as that firsthand financial data remains the most actionable intelligence available given the absence of Item 19 disclosure.

Cereset's growth trajectory from a single licensing-model technology company to a 60-plus unit international franchise system in fewer than seven years of franchising reflects both genuine market demand and systematic brand-building execution. The company opened five new franchise locations in March 2019 alone, bringing the total at that time from eleven to sixteen, a 45% unit growth rate in under two months that signaled early system momentum. By 2025, the brand had expanded beyond the original nine U.S. states that hosted franchises in early 2019, which included Arizona, Arkansas, California, Idaho, Kansas, Michigan, Montana, Texas, and Vermont, to encompass a significantly broader geographic footprint with at least three European locations. The competitive moat for a Cereset franchise is anchored by intellectual property rather than by brand ubiquity. The BrainEcho technology is patented, meaning no competitor can replicate the core service mechanism, and the corporate entity controls both the hardware and the software that franchisees deploy. This creates a single-source dependency that is simultaneously a structural protection and an operational risk concentration point. Cereset Research, which evolved from the HIRREM research program developed under Brain State Technologies, represents a long-term scientific credibility investment that most wellness franchises cannot match: $3 million in research funding has flowed to Wake Forest School of Medicine alone since 2011 through The Susanne Marcus Collins Foundation, and additional support has come from the Office of the Under Secretary of Defense for research into applications relevant to military populations experiencing PTSD and insomnia. The brand's technology has been refined over a 15-year track record of clinical use, a temporal depth of validation that newer neuro-wellness entrants cannot credibly claim. Cereset was also named a Top New Franchise by Entrepreneur magazine, a recognition that elevates brand visibility among the prospective franchisee community and adds to system-level growth momentum.

The ideal Cereset franchise candidate is someone who combines genuine enthusiasm for emerging health technology with the interpersonal skills required to work directly with clients navigating stress, sleep disorders, and neurological imbalance. Cereset explicitly states that prior experience in technology or medical fields is not a prerequisite, prioritizing instead a franchisee's alignment with the brand's wellness philosophy and ability to build trusted relationships within a local community. Owner-operators who are present in their locations and actively engaged with clients are likely to be better positioned for success than passive investors operating at arm's length, given the relationship-intensive nature of the service model and the importance of consistent session delivery quality. The franchise system, with approximately 58 to 60 locations as of 2025, is still in a growth phase that offers genuine territory availability across most U.S. markets, and the corporate team has indicated geographic expansion ambitions that extend the international presence beyond the current three European locations. Cereset encourages local marketing engagement through community events, health presentations, and peer referral networks, which means franchisees in markets with active wellness communities, high household income, or proximity to military installations may find particularly favorable demand conditions. The franchise's research collaboration with military-focused medical institutions at Womack Army Medical Center and Uniformed Services University also creates a potential pathway for franchisees in markets with significant veteran populations to develop institutional referral relationships. Prospective franchisees should initiate conversations with current system operators in diverse markets before committing, as the absence of Item 19 disclosure makes peer validation the primary financial intelligence source available during due diligence.

The Cereset franchise opportunity presents a genuinely differentiated investment thesis in a high-growth industry category: a patented, proprietary technology platform deployed through a franchise model in the fastest-growing segment of the mental health market, with a research-backed clinical foundation that competitors cannot easily replicate. The mental health and neuro-wellness sector is supported by structural tailwinds including the USD 39.22 billion U.S. outpatient psychiatry market growing at 10.63% annually through 2033, increasing consumer acceptance of non-pharmaceutical brain health interventions, and legislative momentum in 14 states enforcing mental health parity. At a total investment ranging from approximately $102,900 to $226,600 with an initial franchise fee of $35,000, Cereset represents a mid-tier capital commitment relative to the wellness franchise category, accessible to qualified investors with focused preparation. The PeerSense Franchise Performance Index has assigned Cereset a score of 64, reflecting a Moderate rating that acknowledges the brand's genuine technology differentiation and market positioning while incorporating the inherent uncertainty of a growth-stage system without Item 19 earnings disclosure. PeerSense provides exclusive due diligence data including SBA lending history, FPI score, location maps with Google ratings, FDD financial data, and side-by-side comparison tools that allow investors to contextualize the Cereset franchise cost and performance profile against comparable wellness and mental health franchise systems. For an investor willing to conduct rigorous franchisee validation and comfortable operating in a category at the leading edge of consumer neuroscience adoption, the Cereset franchise merits serious investigation. Explore the complete Cereset franchise profile on PeerSense to access the full suite of independent franchise intelligence data.